Valdivia J F, Khattak S
Drug Dependency Treatment Program, Building 228, Mail Code 116c, Hines Veterans Administration Hospital, Hines, IL 60141, USA.
Mt Sinai J Med. 2000 Oct-Nov;67(5-6):398-403.
The development and approval of levo-alpha-acetylmethadol (LAAM) as a pharmacotherapeutic agent in opioid agonist therapy provided an alternative to methadone. Clinicians recognized the potential benefits that LAAM, a synthetic mu agonist with pharmacological properties which differ from those of methadone,could have in the treatment management of addicts in opioid agonist therapy. We report our experience utilizing LAAM from 1995 to 1999 at the Hines VA opioid agonist therapy clinic. The addition of LAAM to the clinic's treatment armamentarium has resulted in management options that have improved the areas of patient recruitment, patient retention, patient traffic, take-home medication, detoxification, and treatment outcomes.
左旋-α-乙酰美沙醇（LAAM）作为阿片类激动剂疗法中的一种药物治疗剂的研发与获批，为美沙酮提供了一种替代方案。临床医生认识到，LAAM作为一种合成μ激动剂，其药理特性与美沙酮不同，在阿片类激动剂疗法中对成瘾者的治疗管理可能具有潜在益处。我们报告了1995年至1999年期间在海因斯退伍军人事务部阿片类激动剂治疗诊所使用LAAM的经验。在诊所的治疗手段中加入LAAM后，带来了一些管理选择，这些选择在患者招募、患者留存、患者流量、带回家用药、戒毒及治疗效果等方面都有所改善。
